BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist

Becton, Dickinson and Company (NYSE:BDX) is included among the Top 10 Income Stocks with the Highest Upside Potential.

BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist

On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe lower utilization across the healthcare sector. As a result, BofA is taking a more cautious approach to 2027 estimates for medtech companies, particularly since current valuations already reflect some utilization-related risks.

The analyst also expects inflation to remain a greater headwind in 2027, which could limit margin expansion across the medtech industry. Based on those assumptions, BofA reduced its 2027 estimates for several large-cap companies in its coverage universe that have exposure to both utilization trends and inflation pressures.

Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company. It develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its products are used by healthcare institutions, physicians, life science researchers, clinical laboratories, and other healthcare professionals.

While we acknowledge the risk and potential of BDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and Billionaire Larry Robbins’ 10 Dividend Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1